18:28 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Ra's zilucoplan meets in Phase II for generalized myasthenia gravis, company raises $130M

Ra Pharmaceuticals Inc. (NASDAQ:RARX) said on Dec. 10 that zilucoplan (formerly RA101495 SC) met the primary and key secondary endpoints in a Phase II trial to treat generalized myasthenia gravis. The company plans to meet...
18:41 , Dec 12, 2018 |  BC Extra  |  Financial News

Ra raises $130M on heels of Phase II myasthenia gravis readout

Ra Pharmaceuticals Inc. (NASDAQ:RARX) raised $130 million late Tuesday through the sale of 8.4 million shares at $15.50 in a bumped-up follow-on one day after reporting that its complement C5 (C5) inhibitor met the primary...
21:49 , Apr 20, 2018 |  Company News  |  Company News

Management tracks: Nordic Nanovector, Ra

Blood cancer company Nordic Nanovector ASA (OSE:NANO) appointed CFO Tone Kvåle as interim CEO. Complement-mediated disease company Ra Pharmaceuticals Inc. (NASDAQ:RARX) hired John King as chief commercial officer. King was VP of the U.S. neurology...
23:35 , Apr 5, 2018 |  BC Extra  |  Company News

Management Tracks: CRISPR, Moderna

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) hired Steve Caffé as head of regulatory affairs. Caffé was SVP at Ra Pharmaceuticals Inc. (NASDAQ:RARX). mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) hired Megan Pace as chief...
23:39 , Mar 9, 2018 |  BC Extra  |  Clinical News

Phase I/II of Roche PNH candidate temporarily halted

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said enrollment was temporarily stopped in the Phase I/II COMPOSER trial evaluating RG6107 (SKY59) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) after two patients who received RG6107...
20:25 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Ra raises $50.4M in follow-on

Complement-mediated disease company Ra Pharmaceuticals Inc. (NASDAQ:RARX) raised $50.4 million on Feb. 14 through the sale of 8.4 million shares at $6 in a follow-on underwritten by Credit Suisse, Jefferies, BMO Capital Markets and SunTrust...
19:03 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Ra reports mixed data from Phase II trial of PNH candidate

Ra Pharmaceuticals Inc. (NASDAQ:RARX) reported data from a Phase II trial to treat paroxysmal nocturnal hemoglobinuria (PNH) showing that subcutaneous RA101495 met the primary endpoint of reducing lactate dehydrogenase (LDH) levels from baseline to the...
23:23 , Dec 4, 2017 |  BC Extra  |  Clinical News

Ra falls on interim Phase II PNH data

Ra Pharmaceuticals Inc. (NASDAQ:RARX) lost $5.31 (37%) to $8.92 on Monday after reporting mixed data from a Phase II trial of subcutaneous RA101495 to treat paroxysmal nocturnal hemoglobinuria (PNH). Ra said RA101495 met the primary...
19:56 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Lightstone closes $250M fund

On Sept. 20, Lightstone Ventures (Menlo Park, Calif.) closed Lightstone Ventures II at $250 million. Lightstone said the fund will invest $15-$20 million in each of about 15 early stage biotech and medical device companies....
20:06 , Sep 20, 2017 |  BC Extra  |  Financial News

Lightstone closes $250M fund

Lightstone Ventures closed Lightstone Ventures II at $250 million. Lightstone said the fund will invest $15-$20 million in each of about 15 early stage biotech and medical device companies. The fund has invested in one...